Celularity Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
Celularity Inc. (CELU) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-12-06.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 · last filed 2024-12-06
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2024-09-30 was $0.00.
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2024-06-30 was $0.00.
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2024-03-31 was $0.00.
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2023-12-31 was $0.00.
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2023 was $0.00.
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2022 was $0.00.
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2021 was $0.00.
- Celularity Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2020 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $0.00 derived: sum of 2 quarters · filed 2024-12-06 | $0.00 10-Q · filed 2024-12-06 | $0.00 derived: sum of 4 quarters · filed 2024-12-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 3 quarters · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2024-12-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-10-16 | $0.00 derived: sum of 2 quarters · filed 2024-10-16 | $0.00 derived: sum of 3 quarters · filed 2024-12-06 | $0.00 derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $0.00 derived: sum of 2 quarters · filed 2024-12-06 | $0.00 derived: sum of 3 quarters · filed 2024-12-06 | $0.00 10-K · filed 2024-07-30 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $0.00 derived: sum of 2 quarters · filed 2024-12-06 | $0.00 10-Q · filed 2024-12-06 | $0.00 derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 3 quarters · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $0.00 10-Q · filed 2024-10-16 | $0.00 derived: sum of 2 quarters · filed 2024-10-16 | $0.00 derived: sum of 3 quarters · filed 2024-10-16 | $0.00 derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $0.00 derived: sum of 2 quarters · filed 2024-07-30 | $0.00 derived: sum of 3 quarters · filed 2024-07-30 | $0.00 10-K · filed 2024-07-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $0.00 derived: sum of 2 quarters · filed 2024-01-03 | $0.00 10-Q · filed 2024-01-03 | $0.00 derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-22 | $0.00 derived: sum of 2 quarters · filed 2023-05-22 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |